NCT06430502招募中不适用
Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours
Wuxi People's Hospital1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2024年5月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Relief degree of tumors
研究概览
简要总结
This study is intended to investigate the clinical efficacy of TTV vaccine combined with PD-1/PD-L1 inhibitor in the treatment of relapsed and refractory advanced solid tumours from a clinical perspective.
详细描述
The innovative invention of Tumour Treatment Vaccine (TTV) has been verified in previous studies that the TTV vaccine can play a good role in enhancing the anti-tumour effect of immune checkpoint inhibitor therapy, and the tumour suppression rate of combined anti-PD-1 inhibitor reaches 75.96%. Therefore, this study is intended to investigate the clinical efficacy of TTV vaccine combined with PD-1/PD-L1 inhibitor in the treatment of relapsed and refractory advanced solid tumours from a clinical perspective.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged 18-75 years;
- •Subjects must have histologically- or cytologically-confirmed diagnosis of advanced solid tumor(s) and have progressed on or is not eligible for available standard therapy;
- •Subjects have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (non-nodal lesions with longest diameter ≥ 10 mm, or nodal lesions with short diameter ≥ 15 mm);
- •ECOG score of 0-2, lifespan > 12 weeks;
- •Women of childbearing age who have a negative pregnancy test within 7 days before treatment. Female patients of childbearing age, and male patients with partners of childbearing age must agree to use at least one medically recognized contraceptive method during study treatment and within at least 6 months after the last dose of investigational drug;
- •Voluntarily participated in this study, signed the informed consent form, had good compliance, and cooperated with the follow-up.
排除标准
- •The patient is diagnosed with central nervous system leukemia(symptoms, signs, imaging, cerebrospinal fluid);
- •White blood cell count ≥ 50×10^9/ L or patients with rapid disease progression can't be guaranteed to complete a full treatment cycle;
- •Patients with fungal, bacterial, viral or other uncontrollable infections or requiring four-level isolation treatment.
- •HIV, HBV and HCV positive;
- •Patients with diseases of the central nervous system or autoimmune central nervous system lesions, Including stroke, epilepsy, dementia;
- •Patients have myocardial infection, cardiac angiography or stents, active angina or other obvious clinical symptoms, or have cardiopathic asthma or cardiovascular lymphocytic infiltrates，within 12 months;
- •Patients are on anticoagulation or have severe coagulopathy (APTT>70);
- •Patients in any condition requiring systemic treatment with corticosteroids or other immunosuppressive agents within 2weeks prior to investigational drug administration;
- •Patients were infected with covid-19 within 2weeks prior to investigational drug administration;
- •Subjects having any serious uncontrolled disease or in other conditions that would preclude them from receiving study treatment and are considered unsuitable for this study in the opinion of the investigator;
- •Subjects in other conditions that are considered unsuitable for this study by the investigator.
结局指标
主要结局
Relief degree of tumors
时间窗: immediately after the last treatment
It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST1.1）
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid TumorsSolid Tumors, AdultNCT05747339Wuxi People's Hospital50
Unknown
1 期
Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer TreatmentProstate CancerNCT03525652The First Affiliated Hospital of Guangdong Pharmaceutical University30
已完成
1 期
Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by SurgeryMetastatic Malignant Peripheral Nerve Sheath TumorNeurofibromatosis Type 1Recurrent Malignant Peripheral Nerve Sheath TumorNCT02700230Mayo Clinic30
已完成
2 期
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic MalignancyAcute Myeloid Leukemia (AML)Chronic Myeloid Leukemia (CML)Myelodysplastic SyndromeNCT00433745National Heart, Lung, and Blood Institute (NHLBI)4
已完成
1 期
Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant MelanomaMalignant MelanomaNCT01247623Oslo University Hospital